- Home
- SOR vs ERAS Comparison
SOR vs ERAS Comparison
Compare SOR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- ERAS
- Stock Information
- Founded
- SOR 1968
- ERAS 2018
- Country
- SOR United States
- ERAS United States
- Employees
- SOR N/A
- ERAS N/A
- Industry
- SOR Investment Managers
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- ERAS Health Care
- Exchange
- SOR Nasdaq
- ERAS Nasdaq
- Market Cap
- SOR 368.0M
- ERAS 439.7M
- IPO Year
- SOR N/A
- ERAS 2021
- Fundamental
- Price
- SOR N/A
- ERAS $2.43
- Analyst Decision
- SOR
- ERAS Buy
- Analyst Count
- SOR 0
- ERAS 6
- Target Price
- SOR N/A
- ERAS $3.83
- AVG Volume (30 Days)
- SOR 16.2K
- ERAS 2.3M
- Earning Date
- SOR 01-01-0001
- ERAS 11-11-2025
- Dividend Yield
- SOR 7.24%
- ERAS N/A
- EPS Growth
- SOR N/A
- ERAS N/A
- EPS
- SOR 6.50
- ERAS N/A
- Revenue
- SOR N/A
- ERAS N/A
- Revenue This Year
- SOR N/A
- ERAS N/A
- Revenue Next Year
- SOR N/A
- ERAS N/A
- P/E Ratio
- SOR $6.41
- ERAS N/A
- Revenue Growth
- SOR N/A
- ERAS N/A
- 52 Week Low
- SOR $36.41
- ERAS $1.01
- 52 Week High
- SOR $42.75
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- SOR N/A
- ERAS 73.25
- Support Level
- SOR N/A
- ERAS $2.21
- Resistance Level
- SOR N/A
- ERAS $2.65
- Average True Range (ATR)
- SOR 0.00
- ERAS 0.21
- MACD
- SOR 0.00
- ERAS 0.06
- Stochastic Oscillator
- SOR 0.00
- ERAS 89.39
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.